A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 983 participants.

Also called NCT01649297

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 983 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01649297
  • EudraCT 2012-000905-53
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Canada, Estonia, France, Georgia, Germany, Guatemala, Italy, Latvia, Lithuania, Mexico, New Zealand, Poland, Russia, South Africa, Spain, Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01649297. Randomized; double masking; primary purpose treatment. Start 2012-10 (registry gives no type); primary completion 2013-12 (actual). Results posted on 2015-07-23.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Placebo
Intervention (Drug)
Placebo
Intervention (Drug)
Placebo
Intervention (Drug)
Placebo
Intervention (Drug)
Placebo
Intervention (Drug)
empagliflozin (low dose qd)
Intervention (Drug)
Placebo
Intervention (Drug)
Placebo
Intervention (Drug)
Placebo
Intervention (Drug)
Placebo
Intervention (Drug)
Placebo
Intervention (Drug)
Placebo
Intervention (Drug)
Placebo
Intervention (Drug)
Placebo
Intervention (Drug)
Placebo
Intervention (Drug)
Placebo
Intervention (Drug)
Empagliflozin (high dose qd)
Intervention (Drug)
empagliflozin (high dose bid)
Intervention (Drug)
Placebo
Intervention (Drug)
empagliflozin (low dose bid)
Lead sponsor
Boehringer Ingelheim (class: industry)
Collaborator
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct01649297
Content hash
3854a1f91d1c99a2a762443c5e92357e245c07f4b037d1c3edd324385641071b